OTCMKTS:ARTH - Arch Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.4940 +0.05 (+11.26 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.4940
Today's Range$0.44 - $0.52
52-Week Range$0.25 - $0.89
Volume564,846 shs
Average Volume336,502 shs
Market Capitalization$69.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.58

About Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics logoArch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ARTH
CUSIPN/A
Phone617-431-2313

Debt

Debt-to-Equity RatioN/A
Current Ratio8.82
Quick Ratio8.82

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book49.40

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-211.35%
Return on Assets-108.96%

Miscellaneous

Employees10
Outstanding Shares154,050,000

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics (OTCMKTS:ARTH) posted its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). View Arch Therapeutics' Earnings History.

What price target have analysts set for ARTH?

3 Wall Street analysts have issued 1-year target prices for Arch Therapeutics' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Arch Therapeutics' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Arch Therapeutics.

Who are some of Arch Therapeutics' key competitors?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the folowing people:
  • Dr. Terrence W. Norchi M.D., Co-Founder, Pres, CEO & Director (Age 53)
  • Mr. Richard E. Davis, CFO, Principal Accounting Officer & Treasurer (Age 60)
  • Mr. Rutledge Ellis-Behnke Ph.D., Co-Founder and Scientific Advisor
  • Dr. Steven A. Kates Ph.D., VP of Technology
  • Dr. William Tzocor Denman M.D., MBChB,FRCA, IV, Clinical Advisor (Age 55)

Has Arch Therapeutics been receiving favorable news coverage?

Headlines about ARTH stock have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arch Therapeutics earned a news impact score of 0.09 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.41 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.4940.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $69.69 million. Arch Therapeutics employs 10 workers across the globe.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]


MarketBeat Community Rating for Arch Therapeutics (ARTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arch Therapeutics (OTCMKTS:ARTH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Arch Therapeutics in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 507.29%. The high price target for ARTH is $3.00 and the low price target for ARTH is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.333.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.00$3.00$2.8333
Price Target Upside: 507.29% upside915.23% upside759.60% upside255.18% upside

Arch Therapeutics (OTCMKTS:ARTH) Consensus Price Target History

Price Target History for Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics (OTCMKTS:ARTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/17/2018Roth CapitalReiterated RatingBuyView Rating Details
3/15/2018HC WainwrightSet Price TargetBuy$3.00View Rating Details
3/14/2018Ifs SecuritiesDowngradeStrong-Buy ➝ OutperformView Rating Details
2/13/2017Rodman & RenshawInitiated CoverageBuy$2.50View Rating Details
(Data available from 5/26/2016 forward)

Earnings

Arch Therapeutics (OTCMKTS:ARTH) Earnings History and Estimates Chart

Earnings by Quarter for Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics (OTCMKTS:ARTH) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Arch Therapeutics (OTCMKTS ARTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2017Q3 2017($0.02)($0.01)ViewN/AView Earnings Details
5/2/2017Q2 2017($0.01)($0.01)ViewN/AView Earnings Details
2/1/2017Q1 2017($0.01)ViewN/AView Earnings Details
12/5/2016Q4 2016($0.01)($0.01)ViewN/AView Earnings Details
7/28/2016Q3 2016($0.01)ViewN/AView Earnings Details
4/28/2016Q2 2016($0.01)ViewN/AView Earnings Details
2/12/2016Q1($0.01)ViewN/AView Earnings Details
12/11/2015Q4 2015($0.01)ViewN/AView Earnings Details
8/7/2015Q3 2015($0.02)ViewN/AView Earnings Details
5/7/2015Q2 2015($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arch Therapeutics (OTCMKTS:ARTH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arch Therapeutics (OTCMKTS ARTH) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.02%
Insider Trading History for Arch Therapeutics (OTCMKTS:ARTH)

Arch Therapeutics (OTCMKTS ARTH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Arch Therapeutics (OTCMKTS ARTH) News Headlines

Source:
DateHeadline
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
finance.yahoo.com - May 15 at 8:19 AM
Arch Therapeutics Provides Update on Study Initiation and 510(k)Arch Therapeutics Provides Update on Study Initiation and 510(k)
finance.yahoo.com - May 8 at 8:10 AM
Arch Therapeutics (ARTH) versus Amedica (AMDA) Critical ContrastArch Therapeutics (ARTH) versus Amedica (AMDA) Critical Contrast
www.americanbankingnews.com - May 7 at 3:36 PM
Critical Analysis: Arch Therapeutics (ARTH) and Inovio Pharmaceuticals (INO)Critical Analysis: Arch Therapeutics (ARTH) and Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - April 28 at 1:26 PM
Arch Therapeutics (ARTH) Buy Rating Reiterated at Roth CapitalArch Therapeutics' (ARTH) Buy Rating Reiterated at Roth Capital
www.americanbankingnews.com - April 19 at 6:50 AM
Reviewing Arch Therapeutics (ARTH) and Abiomed (ABMD)Reviewing Arch Therapeutics (ARTH) and Abiomed (ABMD)
www.americanbankingnews.com - April 17 at 3:23 PM
Arch Therapeutics (ARTH) Rating Increased to Hold at Zacks Investment ResearchArch Therapeutics (ARTH) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 1:12 PM
Arch Therapeutics (ARTH) vs. The Competition Head to Head SurveyArch Therapeutics (ARTH) vs. The Competition Head to Head Survey
www.americanbankingnews.com - March 29 at 1:18 AM
Arch Therapeutics (ARTH) Downgraded to "Hold" at Zacks Investment ResearchArch Therapeutics (ARTH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 19 at 5:34 PM
Arch Therapeutics (ARTH) PT Set at $3.00 by HC WainwrightArch Therapeutics (ARTH) PT Set at $3.00 by HC Wainwright
www.americanbankingnews.com - March 15 at 10:30 PM
Arch Therapeutics (ARTH) Downgraded by Ifs Securities to OutperformArch Therapeutics (ARTH) Downgraded by Ifs Securities to Outperform
www.americanbankingnews.com - March 14 at 10:16 PM
IFS Securities Downgrades Arch Therapeutics (ARTH) to OutperformIFS Securities Downgrades Arch Therapeutics (ARTH) to Outperform
www.streetinsider.com - March 14 at 7:13 PM
FDA Places Clinical Hold On ADXS Study, ALT Proves A Good Shot, RYTM On Track - NasdaqFDA Places Clinical Hold On ADXS Study, ALT Proves A Good Shot, RYTM On Track - Nasdaq
www.nasdaq.com - March 13 at 8:17 AM
Form 8-K Arch Therapeutics, Inc. For: Mar 12 - StreetInsider.comForm 8-K Arch Therapeutics, Inc. For: Mar 12 - StreetInsider.com
www.streetinsider.com - March 13 at 8:17 AM
Arch Therapeutics Provides Update on 510(k) - GlobeNewswire (press release)Arch Therapeutics Provides Update on 510(k) - GlobeNewswire (press release)
www.globenewswire.com - March 13 at 8:17 AM
Arch Therapeutics Provides Update on 510(k) - NasdaqArch Therapeutics Provides Update on 510(k) - Nasdaq
www.nasdaq.com - March 12 at 6:44 PM
Arch Therapeutics Provides Update on 510(k)Arch Therapeutics Provides Update on 510(k)
finance.yahoo.com - March 12 at 6:44 PM
Form 4 Juno Therapeutics, Inc. For: Mar 05 Filed by: NELSEN ROBERTForm 4 Juno Therapeutics, Inc. For: Mar 05 Filed by: NELSEN ROBERT
www.streetinsider.com - March 9 at 6:58 PM
Arch Therapeutics (ARTH) Downgraded by Zacks Investment Research to "Hold"Arch Therapeutics (ARTH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 9 at 6:48 PM
Arch Therapeutics (ARTH) Rating Increased to Buy at Zacks Investment ResearchArch Therapeutics (ARTH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 8 at 6:41 PM
Reviewing Zynex (ZYXI) & Arch Therapeutics (ARTH)Reviewing Zynex (ZYXI) & Arch Therapeutics (ARTH)
www.americanbankingnews.com - March 6 at 1:24 PM
Analyzing Arch Therapeutics (ARTH) and Zynex (ZYXI)Analyzing Arch Therapeutics (ARTH) and Zynex (ZYXI)
www.americanbankingnews.com - March 6 at 5:14 AM
Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018 - GlobeNewswire (press release)Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018 - GlobeNewswire (press release)
globenewswire.com - March 5 at 8:12 AM
Head-To-Head Review: Arch Therapeutics (ARTH) vs. Zynex (ZYXI)Head-To-Head Review: Arch Therapeutics (ARTH) vs. Zynex (ZYXI)
www.americanbankingnews.com - February 27 at 10:10 AM
Zacks Investment Research Downgrades Arch Therapeutics (ARTH) to HoldZacks Investment Research Downgrades Arch Therapeutics (ARTH) to Hold
www.americanbankingnews.com - February 21 at 6:04 PM
Arch Therapeutics (ARTH) Upgraded at Zacks Investment ResearchArch Therapeutics (ARTH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 20 at 5:08 PM
Contrasting Zynex (ZYXI) and Arch Therapeutics (ARTH)Contrasting Zynex (ZYXI) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - February 16 at 5:12 PM
Zynex (ZYXI) and Arch Therapeutics (ARTH) Critical SurveyZynex (ZYXI) and Arch Therapeutics (ARTH) Critical Survey
www.americanbankingnews.com - February 16 at 5:12 PM
Arch Therapeutics (ARTH) Upgraded to Strong-Buy by Ifs SecuritiesArch Therapeutics (ARTH) Upgraded to Strong-Buy by Ifs Securities
www.americanbankingnews.com - February 11 at 9:36 AM
Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics ... - GlobeNewswire (press release)Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics ... - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:37 PM
Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical ApplicationDermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application
finance.yahoo.com - February 5 at 8:58 AM
Arch Therapeutics Inc (ARTH) Receives Consensus Rating of "Buy" from AnalystsArch Therapeutics Inc (ARTH) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 19 at 8:18 AM
Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January ... - GlobeNewswire (press release)Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January ... - GlobeNewswire (press release)
globenewswire.com - January 2 at 4:59 PM
Arch Therapeutics, Inc. (ARTH) Given Consensus Rating of "Buy" by BrokeragesArch Therapeutics, Inc. (ARTH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 25 at 8:06 AM
Arch Therapeutics (ARTH) Stock Rating Lowered by Zacks Investment ResearchArch Therapeutics (ARTH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - December 22 at 7:00 PM
HC Wainwright Analysts Give Arch Therapeutics (ARTH) a $3.00 Price TargetHC Wainwright Analysts Give Arch Therapeutics (ARTH) a $3.00 Price Target
www.americanbankingnews.com - December 19 at 7:28 PM
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA - GlobeNewswire (press release)Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA - GlobeNewswire (press release)
globenewswire.com - December 19 at 11:18 AM
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA - NasdaqArch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA - Nasdaq
www.nasdaq.com - December 18 at 11:06 AM
Financial Review: Arch Therapeutics (ARTH) & Integer (ITGR)Financial Review: Arch Therapeutics (ARTH) & Integer (ITGR)
www.americanbankingnews.com - December 15 at 3:30 PM
Head-To-Head Review: Arch Therapeutics (ARTH) versus AxoGen (AXGN)Head-To-Head Review: Arch Therapeutics (ARTH) versus AxoGen (AXGN)
www.americanbankingnews.com - December 15 at 9:46 AM
Contrasting Integer (ITGR) and Arch Therapeutics (ARTH)Contrasting Integer (ITGR) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - December 11 at 7:42 PM
Critical Contrast: Arch Therapeutics (ARTH) versus AxoGen (AXGN)Critical Contrast: Arch Therapeutics (ARTH) versus AxoGen (AXGN)
www.americanbankingnews.com - December 8 at 5:14 PM
Reviewing Arch Therapeutics (ARTH) & AxoGen (AXGN)Reviewing Arch Therapeutics (ARTH) & AxoGen (AXGN)
www.americanbankingnews.com - December 8 at 8:40 AM
AxoGen (AXGN) vs. Arch Therapeutics (ARTH) Head to Head ContrastAxoGen (AXGN) vs. Arch Therapeutics (ARTH) Head to Head Contrast
www.americanbankingnews.com - December 7 at 5:30 PM
Arch Therapeutics (ARTH) Lifted to "Buy" at Zacks Investment ResearchArch Therapeutics (ARTH) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - December 1 at 8:42 PM
Contrasting Arch Therapeutics (ARTH) & AxoGen (AXGN)Contrasting Arch Therapeutics (ARTH) & AxoGen (AXGN)
www.americanbankingnews.com - November 30 at 5:28 PM
Reviewing Integer (ITGR) and Arch Therapeutics (ARTH)Reviewing Integer (ITGR) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 29 at 7:26 PM
Analyzing AxoGen (AXGN) and Arch Therapeutics (ARTH)Analyzing AxoGen (AXGN) and Arch Therapeutics (ARTH)
www.americanbankingnews.com - November 28 at 7:10 PM
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7 ... - GlobeNewswire (press release)Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7 ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 6:13 PM
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017
finance.yahoo.com - November 28 at 9:25 AM

SEC Filings

Arch Therapeutics (OTCMKTS:ARTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Arch Therapeutics (OTCMKTS ARTH) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.